APOGENIX
Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death (a.k.a. apoptosis - ἁπόπτωσισ is used in Greek to describe the "falling off" of leaves from trees) or on the inhibition of tumour cell growth. The lead product candidate of the company, APG101, is currently in a controlled phase II proof of concept study with GBM patients (GBM: Glioblastoma multiforme).
APOGENIX
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.apogenix.com
Total Employee:
51+
Status:
Active
Contact:
+49 6221 58608-0
Total Funding:
38 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro COVID-19 Joomla!
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Ascletis
Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.
Biomica
Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases.
GeNeuro
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Nanobiotix
Nanobiotix is a nanomedicine company developing novel therapeutics for the local treatment of cancer.
Neovacs
Neovacs, a biotech company, develops several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune and allergic diseases.
Oncodesign
Oncodesign develops anticancer therapies for the treatment of patients with cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
German Federal Ministry of Education and Research
German Federal Ministry of Education and Research investment in Grant - Apogenix
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding investment in Series C - Apogenix
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding investment in Series B - Apogenix
Official Site Inspections
http://www.apogenix.com Semrush global rank: 10.13 M Semrush visits lastest month: 257
- Host name: 213.160.74.20
- IP address: 213.160.74.20
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Apogenix"
Company Profile ǀ Apogenix
The Apogenix team has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and viral infections.See details»
Apogenix - Crunchbase Company Profile & Funding
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. View contacts for Apogenix to access new leads and …See details»
Apogenix ǀ Immuno-oncology therapeutics for the treatment of …
Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target …See details»
Apogenix Company Profile 2024: Valuation, Funding & Investors
Apogenix General Information Description. Developer of immuno-oncology therapeutics designed to treat cancer and other malignant diseases. The company's platform targets critical …See details»
Apogenix - Overview, News & Similar companies | ZoomInfo.com
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of solid tumors and hematological malignancies. The company's pipeline of immuno …See details»
Apogenix AG - life-sciences-europe.com
Dec 23, 2015 Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company’s pipeline of …See details»
Apogenix - Products, Competitors, Financials, Employees, …
About Apogenix. Apogenix is a company focused on the development of immuno-oncology therapeutics in the healthcare and biotechnology industry. The company's main offerings …See details»
Apogenix Company Profile - Office Locations, Competitors ... - Craft
Apogenix has 5 employees at their 1 location and $55.72 m in total funding,. See insights on Apogenix including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Apogenix Advances Clinical Development of CD95L Inhibitor …
Oct 13, 2020 Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company's pipeline of …See details»
Management Board - Apogenix
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant …See details»
Apogenix to Start European Clinical Phase II Trial with Asunercept …
Jul 28, 2020 HEIDELBERG, GERMANY / ACCESSWIRE / July 28, 2020 / Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced …See details»
Apogenix AG - BIO CEO & Investor Conference | BIO
Feb 7, 2023 Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company’s pipeline of …See details»
Apogenix offers new routes to cancer immunotherapy
Apogenix GmbH Heidelberg, Germany Tel: + 49 (0) 6221 586080 Email: [email protected] Checkpoint inhibition with APG101. By blocking the CD95 …See details»
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in ...
Oct 24, 2024 8 Apogenix GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg, Germany. 9 Cytel Inc., 950 Winter St, Waltham, ... to categories 4-6 of a clinical severity assessment scale …See details»
Apogenix offers new routes to cancer immunotherapy - Nature
One is an immunohistochemical assay for the presence of CD95L in the tumors of glioblastoma patients, and the second is a methylation-based epigenetic marker.Apogenix also has …See details»
Scientific Advisors - Apogenix
In addition to his academic research activities, Prof. Walczak served as CEO/CSO for Apogenix Biotechnology AG, the predecessor of Apogenix GmbH, from 2000 to 2004. In 2007, he …See details»
Apogenix Receives FDA Orphan Drug Designation for Apocept™ …
Feb 7, 2013 Apogenix, a spin-out from the German Cancer Research Center (DKFZ), is developing novel protein therapeutics for the treatment of cancer and inflammatory diseases …See details»
Pipeline ǀ Apogenix
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant …See details»
Press Releases - Apogenix
Oct 18, 2018 2023. June 1, 2023. Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model. March 27, 2023. Apogenix’ Partner …See details»